Clinical Trial Update: High Dose of Erythropoietin Analogue After Cardiac Arrest [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a high-dose erythropoietin analogue in comatose survivors of cardiac arrest has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Arrest

Drugs mentioned

• Erythropoietin analogue (erythropoietin analogue)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Comatose Survivors of Cardiac Arrest | Phase 3 | Status: COMPLETED